The interface between the polymerase I associated factor Rrn3 and the 43 kDa subunit of RNA polymerase I is essential to the recruitment of Pol I to the preinitiation complex on the rDNA promoter. In silico analysis identified an evolutionarily conserved 22 amino acid peptide within rpa43 that is both necessary and sufficient to mediate the interaction between rpa43 and Rrn3. This peptide inhibited rDNA transcription in vitro while a control peptide did not. To determine the effect of the peptide in cultured cells, the peptide was coupled to the HIV TAT peptide to facilitate transduction into cells. The wild type peptide, but not control peptides, inhibited Pol I transcription and cell division.
Introduction
Pleiomorphic nucleoli, a marker of the malignant phenotype for over a century (1) , result from the high rate of ribosome biogenesis associated with cancer. Ribosome biogenesis is a tightly regulated, energetically costly process (2) (3) (4) . The rate-limiting step in ribosome biogenesis is the synthesis of 47S pre-rRNA, the precursor of the 18S, 5.8S and 28S rRNAs, by RNA polymerase I (Pol I) (5) (6) (7) . Indeed, recent studies have shown that selectively targeting Pol I transcription is a promising avenue for the therapeutic treatment of hematologic malignancies (8, 9) . The targeting of Pol I transcription for cancer therapy will require complementary approaches. This in turn requires detailed knowledge of the key regulatory steps in Pol I transcription to allow for the rational design of selective inhibitors.
Transcription by RNA polymerase I requires Pol I-specific transcription factors (2, (10) (11) (12) . In mammals, the cooperative interaction between two transcription factors is required to efficiently commit the rDNA promoter (13) (14) (15) ; SL1, containing TBP and TBP-associated factors (TAFs), and UBF (15) . Pol I transcription is subject to multiple levels of regulation (16) (17) (18) (19) (20) , including regulation by both anti-oncogenes and oncogenes (21) (22) (23) (24) .
The recruitment of Pol I to the committed template is complex (25, 26) and references therein). Only those polymerase molecules that contain Rrn3, a polymerase-associated factor, are capable of promoter-specific transcription (26) . Hence, Rrn3 is essential for rDNA transcription (27, 28) . Rrn3 acts as a bridge between RNA polymerase I and the committed rDNA promoter (29) (30) (31) . Rrn3 interacts with the 43-kDa subunit of RNA polymerase I (rpa43) and with the TAF I 110 and TAF I 68 subunits of mammalian SL1.
Further, Rrn3 is a DNA-binding protein and DNA-binding by Rrn3 is required for transcription (32) . The predominant model is that active Rrn3 functions in the correct recruitment of RNA polymerase I to the committed template (33, 34) .
We found that the binding site of mouse rpa43 to Rrn3 required a conserved region of 22 amino acids in mouse rpa43. We hypothesized that if this 22 amino acid peptide could sequester Rrn3, then the addition of the peptide would block rDNA transcription in vitro. When this was tested, we observed that the addition of the wild-type peptide, but not a peptide consisting of random amino acids (randomized 22mer/Ψ), to an in vitro transcription reaction blocked rDNA transcription in a dose-dependent manner. In order to study the effect of the peptide in intact cells, we fused the 22mer to a cell transducing peptide based on the HIV TAT protein transduction domain (35) .
Transduction of the 22mer into cultured cells resulted in the dose-dependent inhibition of rDNA transcription. Interestingly, the peptide demonstrated differential effects on cell growth. The peptide inhibited the growth of non-transformed cells, e.g. WI38 cells. In contrast, rat, mouse and human tumor cell lines underwent cell death within 8-48hrs in response to the peptide, but not in response to control peptides. The rate at which the cells died was not proportional to the rate of cell division. Our data indicate that the introduction into cells of a peptide that can bind to Rrn3, based on the sequence of rpa43, has the ability to inhibit rDNA transcription and induce cell death and has the potential to form the basis of a novel therapeutic mechanism to selectively treat cancer cells.
Materials and Methods

Yeast two-hybrid studies of protein-protein interactions
The Hybrid Hunter System (Invitrogen) was used to study the interaction between mouse rpa43 (mRPA43) and human Rrn3 (hRrn3) or mouse Rrn3 (mRrn3). The bait was a fusion protein consisting of the a LexA DNA-Binding Domain (DBD) and mRPA43. The prey was a fusion between the B42 activation domain (AD) and human or mouse Rrn3. S. cerevisiae L40 cells were transformed with pHybLexA/zeo driving the expression of the bait, and maintained in the presence of zeocin. These cells were then transformed with pYesTrp2 harboring the prey and allowing for selection by tryptophan prototrophy (W). The interaction of bait and prey proteins results in the expression of the reporter genes, HIS3 and LacZ, which can be detected by selection on plates lacking histidine (YC-WHU+Z), or by assaying for β-galactosidase activity (36) .
Pull-down Assays
FLAG tagged Rrn3 was expressed in Sf9 cells and purified as previously described (37) . Pull-down assays using biotin coupled peptide were carried out using avidincoated beads and the protocol recommended by the supplier (Invitrogen). SDS-PAGE and electroblotting were carried out as described previously (21) . Antibodies to caspase 3 and PARP (Cell Signaling) and FLAG (Sigma) were used as recommended by the suppliers.
Tissue culture and the measurement of cell proliferation
In some experiments, cell numbers were obtained using either a haemocytometer or a Cellometer (Nexcelom Bioscience LLC) and counterstaining with trypan blue. In other experiments, cell numbers were measured using the cyquant assay (Molecular ProbesInvitrogen) using the protocol recommended by the supplier. Cells counted with a haemocytometer were used to calibrate the assay. N1S1 cells (CRL-1604) and WI-38 cells (CL-75) were obtained from the ATCC. Mouse lymphosarcoma P1798 cells were a gift from Dr Aubrey Thompson, Jr. The human B-lymphoma cell lines used in this study were provided by Dr. Carol Webb (OMRF) and have been characterized as follows:
Daudi, EBV-positive, LMP1-negative, Burkitt lymphoma (38); K562 and Raji, Burkitt's lymphoma; and CL-01, EBV positive.
Twenty-four hours prior to treatment, adherent cells were plated at approximately 30-40% confluency. Suspenson cells were plated at 3-6x10 5 cells /ml. Cells were then treated as indicated. Detection of apoptotic, DNA fragmentation was carried out as described (39) .
In vitro rDNA transcription S100 extracts from N1S1 cells were prepared essentially as described (40, 41) . In vitro transcription reactions were carried as described previously using 0.1 μg template/assay (41) . The amount of radioactive uridine incorporated into RNA was determined by TCA precipitation on GFC filters and liquid scintillation spectrophotometry. Alternatively, whole cell RNA was isolated (36) and the specific radioactivity of the isolated RNA was determined. In a third assay, after 2x10 
Results
Interaction between RPA43 with Rrn3 in Yeast Two Hybrid System
In the yeast two hybrid system, human Rrn3 and mouse Rrn3 interacted with mouse rpa43 (Figure 1 ). Yeast L40 cells transformed with pHybLex mRPA43 and pYesTrp2 hRrn3 produced colonies on the selective plate, YC-WHU+Zeocin (histidine selection medium, Right side, top panel, Figure 1A ), but the cells transformed with pHybLex mRPA43 and empty pYesTrp2 did not grow in the absence of histidine (Left side, top panel, Figure 1A ). This confirms that the protein-protein interaction between mRPA43 and hRrn3 can be studied in this system. The control cells transformed with pYesTrp2 hRrn3 grew on YC-WU (Left side, bottom panel, Figure 1A ) but did not grow on YC-WHU medium (Right side, bottom panel, Figure 1A ). This demonstrates that pYesTrp2 Figure 1C ). These results support our hypothesis that the 22 conservative amino acids play an important role in the interaction between rrn3 and rpa43. These results were confirmed in pull down assays ( Figure 1D ), in which cotransfected Rrn3 coimmunoprecipitated with wild-type rpa43, but not with either of the mutants.
Incorporation of rpa43, rpa43Δ and rpaΨ into Pol I
To determine if the mutagenesis of amino acids 136 to 157 affected the overall structure of rpa43, we examined the interactions of wild type, rpa43Δ and rpa43Ψ with Pol I . 3T3 cells were transfected with vectors driving the expression of FLAG-tagged versions of the constructs. Lysates from the transfected cells were immunoprecipitated with antirpa43 antiserum bound to protein G agarose beads and the precipitates were analyzed by western blotting. Anti-rpa127 antiserum (42) was used to report for Pol I and anti-FLAG antibodies were used to report for rpa43 ( Figure 1E ). Both wild type rpa43 and the randomization mutant (rpa43Ψ) were immunoprecipitated with anti-rpa43 serum and Pol I (rpa127) coimmunoprecitatecd with both (lane 2 and 3). These data demonstrated that ectopically expressed, mutant forms of rpa43 can be incorporated into Pol I, and serve as controls demonstrating that the mutants are not significantly misfolded. The above experiments demonstrated that amino acids 136 to 157 of rpa43 were required for the interaction with Rrn3. We next asked if this region was sufficient for the interaction with Rrn3. The 22mer was synthesized with an N-terminal biotin and bound to avidin coated beads. In parallel, FLAG-Rrn3 was purified from infected Sf9 cells cells (32) . The FLAG-Rrn3 was then incubated with blank avidin-coated beads or with beads that had been incubated with biotin-22mer (Figure 2 A, cartoon). The proteins that bound to the beads were analyzed by western blotting. Rrn3 did not bind to blank beads, but did bind to the peptide coated beads ( Figure 2A , lanes 2 and 3). These results indicated that amino acids 136 to 157 (22mer) were sufficient to bind Rrn3.
Taken together with the previous results, this domain is both necessary and sufficient to bind Rrn3.
The "22mer" can inhibit transcription in vitro.
The binding of Rrn3 to RNA polymerase I is essential for the recruitment of Pol I to a committed template (33, 34) . As our data indicated that the 22mer itself could bind Rrn3, we considered that addition of an excess amount of the 22mer to a transcription reaction would block transcription by competing with the polymerase associated rpa43
for Rrn3. This was tested using an in vitro transcription system. In this system, if the 22mer interacted with Rrn3, it would sequester it. In turn, the sequestration of Rrn3 would result in an inhibition of rDNA transcription. As shown in Figure 2 , the addition of increasing amounts of wild type peptide inhibited rDNA transcription (lanes 2-5), while the addition of the Ψ peptide did not inhibit transcription (lanes 6-9). of the TAT-22mer on the labeling of the 47/45S pre-rRNA precursor. As shown in Figure 3C , treatment with the TAT-22mer inhibited incorporation into the 47/45S precursor by 70%. This is direct evidence that we have targeted rDNA transcription.
The "22-mer" can reversibly inhibit cell proliferation in vivo.
Several laboratories have demonstrated that the inhibition of rDNA transcription, using either shRNAs or small molecules targeting components of the rDNA transcription apparatus, prevents cell proliferation (8, 9) . We tested the possibility that the 22merwould have a similar effect. WI38 cells were incubated with varying doses of the TAT-22mer or TAT peptide. As shown in Figure 4A , the cells treated with TAT-22mer ceased to proliferate after 72 hours of treatment. While we did not observe a significant increase in trypan blue uptake, it was formally possible that the apparent inhibition of cell division was due to a combination of cell death and the inhibition of cell division. FACS analysis (data not shown) did not demonstrate either a specific block in cell cycle progression or an increase in the number of apoptotic cells (cells with subG 0 /G 1 amounts of DNA). Thus, the decrease in proliferation was most likely not due to an increase in apoptotic cell death. Subsequently, we asked if the effect was reversible; would the cells reinitiate proliferation if we removed TAT-22mer from the medium?
Twenty-four hours after WI38 cells were plated, vehicle, 90 mM TAT peptide or 90mM TAT-22mer was added to the media. After 72 hours of treatment (96 hr), duplicate wells were counted, and then the media on the treated cells was replaced with fresh media.
The cell numbers were determined in these "recovering" wells after 24 and 48 hr. As shown in Figure 4B 
Treatment with the TAT-22-mer causes tumor cell death.
It has been reported that the inhibition of ribosome biogenesis can result in cell death; a phenomenon that is sometimes referred to as nucleolar stress (8, (43) (44) (45) When mouse lymphoma cells (P1798 cells), were treated with varying doses of TAT22mer for 24 hours, we found that the cell number was greatly reduced from the starting density and more than 90% of the "surviving" cells failed to exclude trypan blue (data not shown). When we carried out time course studies to determine when the P1798 cells began to die after being treated with the TAT-22mer, we found that the cell number Figure 5G .
Mechanism of cell death.
Donati et al. have reported that the inhibition of ribosome biogenesis causes cell death through both p53-dependent and p53-independent apoptotic pathways triggered by nucleolar stress (43, 44) . The N1S1 cells are p53 wild type. In order to determine if the cells were undergoing apoptotic death, we examined assayed for several apoptosis markers, e.g. caspase 3 and PARP cleavage, the formation of DNA ladders and propidium iodide-annexin V staining. As a positive control for apoptosis, cells were treated with staurosporine , a non-specific phosphatase inhibitor (46) . lanes 3 and 4) . Similarly, treatment with TAT-22mer or staurosporine resulted in PARP cleavage ( Figure 6B, lanes 3 and 4) and DNA fragmentation ( Figure 6C, lanes 2 and 4 ) . When N1S1 cells were treated with staurosporine, there was a significant increase in a population of cells that stained with annexin V, but not propidium iodide (lower right quadrant) that was not observed when the cells were treated with vehicle or TAT-eGFP ( Figure 6D ). However, when the cells were treated with TAT-22mer two populations were observed; one that stained with annexin V and a second population that stained with both annexin V and propidium iodide. This is consistent with both apoptosis (the shift to the lower right quadrant) and necrosis (the shift to the upper right quadrant).
We examined the possibility that the inhibition of rRNA synthesis by the TAT-22mer induced apoptosis in other cell lines. As shown in Figure 7 , we measured the levels of activated caspase 3 in P1798 cells treated with the peptide for 3 hours, a time point in which we see a significant percent of cell death. Treatment with either the TAT peptide or TAT-22mer did not cause the activation of caspase 3 as shown in Figure 7A . In contrast, treatment with staurosporine for three hours caused the accumulation of cleaved caspase 3 (lanes 2 and 3) . Similarly, we did not find evidence for PARP cleavage when P1798 cells were treated with TAT-22mer ( Figure 7B that these amino acids would be important for the interaction with Rrn3, we found that these 22 amino acids are necessary and sufficient for rpa43 to bind to Rrn3 in either pull-down assays or in a yeast two hybrid system. While our data demonstrate the importance of the 22 amino acids in the interaction with Rrn3, neither deletion nor randomization mutants of the 22mer inhibited the incorporation of rpa43 into endogenous RNA polymerase I, arguing that the mutant forms of rpa43 are not fully misfolded.
As the basic model for transcription by Pol I requires an interaction between Rrn3 and rpa43, we examined the possibility that an excess amount of the 22mer would inactivate transcription when added to an in vitro transcription reaction. Our rationale was that the peptide would compete with rpa43-Pol I for Rrn3 in the reaction. Once we confirmed that this had happened, we next sought to determine if this could be duplicated in vivo.
To facilitate entry of the peptide into living cells, we added the cell penetrating peptide from the transactivator of transcription (TAT) of human immunodeficiency virus to the 22mer (TAT-22mer). When N1S1 hepatoma cells were treated with the peptide we observed a robust and dose-dependent inhibition of RNA synthesis. TAT peptide by itself, or other control peptides, had no effect on RNA synthesis. As rRNA synthesis is approximately 70% of the total RNA synthesis in these cells, the fact that we observed 60% inhibition of incorporation of [ (data not shown); we failed to observe the generation of the 38S and 30S processing products. This suggests that the residual labeling of 47/45S rRNA that we have observed, might in fact be caused by the accumulation of the precursor due to the lack of processing, and that the inhibition of pre-rRNA synthesis was greater than 70%.
Quantitative RT-PCR analysis of several mRNAs, e.g. GAPDH, actin or peptidylprolyl isomerase, failed to demonstrate any significant changes in the steady state-levels of those mRNAs (data not shown); consistent with the model that we had not inhibited transcription by Pol II.
In the simplest model, one might predict that the inhibition of rDNA transcription and the resultant inhibition in the accumulation of ribosomes would result in the inhibition of cell cycle progression. In fact, this is what we observed when we treated WI38 cells with the peptide for periods up to 72 hours, and we did not observe an increased percentage of cells staining with trypan blue. It has been reported that the inhibition of rDNA transcription can lead to cell death via apoptosis (43, 47) . However, FACS analysis did not demonstrate an increased number of subG 1 cells, and when we removed the peptide from the media, the WI38 cells resumed cell division, suggesting that there had not been a significant amount of cell death.
In contrast, we found that when transformed cell lines, including a rat hepatoma, a mouse lymphoma and various human hematological malignancies were treated with the peptide, they demonstrated cell death. In some cases, more than 90% of the cells stained with trypan blue after six hours of treatment. However, the time to 90% cell death varied. Our first model was that the time to cell death would be proportional to cell cycle time; more rapidly dividing cells would be more dependent upon a constant supply interaction and possibly others that mediate initiation or elongation may provide additional, specific molecular targets through which rDNA transcription can be targeted.
As mentioned above, the inhibition of rDNA transcription leads to cell death through apoptotic pathways, both p53-dependent as well as p53-independent pathways (43, 44, 47) . When we examined the effects of the TAT-22mer on N1S1 cells, we observed caspase and PARP cleavage and DNA degradation ladders consistent with apoptosis.
In addition, we observed annexin V-propidium staining FACS analyses consistent with apoptosis. Western blots demonstrated that these cells contain wild-type p53. However, we have been unable to demonstrate apoptosis in p1798 lymphoma cells that also contain wild-type p53. We have not observed DNA-laddering, caspase activation or PARP cleavage in cells that are clearly dying, i.e. failing to exclude trypan blue. Further, when the cells were sorted by annexin V/propidium iodide staining, the TAT-22mer treated cells demonstrated a shift consistent with necrosis. The Raji, Cl-01, Daudi and K562 cells we have used, have all been reported to be p53 mutants (51) . Hence, it is possible that the inhibition of rDNA transcription by the peptide will induce apoptosis through p53-independent pathways as described by Donati et al. (44, 47) . This needs to be examined in greater detail. p53 is mutated in many human tumors and defects in p53-dependent apoptotic pathway(s) present an obstacle for cancer therapeutics.
Hence, the finding that disruption of the Rrn3-rpa43 interaction leads to cell death in p53 mutant cells opens the possibility of a novel chemotherapeutic pathway. 
